The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Evidence for Abnormal Left Ventricular Structure and Function in Normotensive Individuals with Familial Hyperaldosteronism Type I
Abstract
OBJECTIVES: To explore whether aldosterone excess can induce adverse cardiovascular effects independently of effects on blood pressure (BP), we sought evidence of disturbed cardiovascular structure or function in normotensive individuals with primary aldosteronism. METHODS: Eight normotensive subjects with genetically proven familial hyperaldosteronism type I (FH-I) were compared with 24 age- and sex-matched normotensive controls in terms of BP, biochemical parameters, pulse wave velocity, and echocardiographic characteristics. RESULTS: Subjects with FH-I demonstrated higher serum aldosterone levels and aldosterone/renin ratios than controls, as expected. Despite having similar 24-h ambulatory BPs, subjects with FH-I demonstrated evidence of concentric remodeling with greater septal (mean +/- sd, 9.4 +/- 1.1 vs. 7.9 +/- 0.9 mm; P < 0.001), posterior wall (9.2 +/- 1.7 vs. 7.7 +/- 1.0 mm; P < 0.01), and relative wall (0.29 +/- 0.03 vs. 0.24 +/- 0.02; P < 0.001) thicknesses, and lower mitral early peak velocities (0.74 +/- 0.10 vs. 0.90 +/- 0.16 m/sec; P < 0.05), ratios of early to late peak diastolic transmitral flow velocity (1.56 +/- 0.24 vs. 2.06 +/- 0.41; P < 0.01), and myocardial early peak velocities (8.3 +/- 1.8 vs. 10.3 +/- 2.6 cm/sec; P < 0.05). There were no significant differences in pulse wave velocity or left ventricular ejection fraction, long axis strain rate, peak systolic strain, cyclic variation of integrated backscatter, or posterior wall calibrated integrated backscatter. CONCLUSIONS: Aldosterone excess is associated with increased left ventricular wall thicknesses and reduced diastolic function, even in the absence of hypertension.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings
Devereux, R. B., Alonso, D. R., Lutas, E. M., Gottlieb, G. J., Campo, E., Sachs, I., & Reichek, N. (1986) · The American Journal of Cardiology · doi:10.1016/0002-9149(86)90771-x · Cited by 6,229
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
(2004) · PsycEXTRA Dataset · doi:10.1037/e442802008-001 · Cited by 2,875
Weber, K. T., & Brilla, C. G. (1991) · Circulation · doi:10.1161/01.cir.83.6.1849 · Cited by 2,027
Lifton, R. P., Dluhy, R. G., Powers, M., Rich, G. M., Cook, S., Ulick, S., & Lalouel, J.-M. (1992) · Nature · doi:10.1038/355262a0 · Cited by 1,158
Zannad, F., Alla, F., Dousset, B., Perez, A., & Pitt, B. (2000) · Circulation · doi:10.1161/01.cir.102.22.2700 · Cited by 947
Pitt, B., Wj, R., Zannad, F. M., Neaton, J. D., Martínez, F. A., Roniker, B., Bittman, R. M., Hurley, S., Kleiman, J. H., & Gatlin, M. R. (2003) · Cited by 708
Cited by
Funder, J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., Stowasser, M., & Young, W. F. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4061 · Cited by 2,925
“Why is primary aldosteronism important? This condition is important not only because of its prevalence, but also because patients with PA have higher cardiovascular morbidity and mortality than age- and sexmatched patients with essential hypertension and the same degree of BP elevation (30, 31).”
BackgroundSelf-citationFunder, J. W., Carey, R. M., Fardella, C., Gomez-Sanchez, C. E., Mantero, F., Stowasser, M., Young, W. F., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0104 · Cited by 1,554
Self-citationHypertension: Renin–Angiotensin–Aldosterone System Alterations
te Riet, L., van Esch, J. H. M., Roks, A. J. M., van den Meiracker, A. H., & Danser, A. H. J. (2015) · Circulation Research · doi:10.1161/circresaha.116.303587 · Cited by 706
Primary aldosteronism: renaissance of a syndrome
Young, W. F. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02775.x · Cited by 680
Douma, S., Petidis, K., Doumas, M., Papaefthimiou, P., Triantafyllou, A., Kartali, N., Papadopoulos, N., Vogiatzis, K., & Zamboulis, C. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60834-x · Cited by 560
Diagnosis and treatment of primary aldosteronism: practical clinical perspectives
Young, W. F. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12831 · Cited by 325
Observational Study Mortality in Treated Primary Aldosteronism: The German Conn's Registry
Reincke, M., Fischer, E., Gerum, S., Merkle, K., Schulz, S., Pallauf, A., Quinkler, M., Hanslik, G., Lang, K., Hahner, S., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.197111 · Cited by 278
Mihailidou, A. S., Loan Le, T. Y., Mardini, M., & Funder, J. W. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.136242 · Cited by 262
Laboratory challenges in primary aldosteronism screening and diagnosis
Rehan, M., Raizman, J. E., Cavalier, E., Don-Wauchope, A. C., & Holmes, D. T. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.01.003 · Cited by 89
Future of Cholesteryl Ester Transfer Protein Inhibitors
Rader, D. J., & deGoma, E. M. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-163305 · Cited by 66
Aldosterone: A cardiovascular risk factor?
Funder, J. W., & Reincke, M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.08.005 · Cited by 47
Ahn, S. H., Kim, J. H., Baek, S. H., Kim, H., Cho, Y. Y., Suh, S., Kim, B.-J., Hong, S., Koh, J.-M., Lee, S. H., et al. (2018) · Yonsei Medical Journal · doi:10.3349/ymj.2018.59.4.501 · Cited by 43
“It is also known that aldosterone excess itself has an adverse effect on cardiac function in normotensive patients with PA.(36) Therefore, proper diagnosis and active management of this disease are needed.”
Primary Aldosteronism: Cardiovascular Outcomes Pre- and Post-treatment
Hundemer, G. L. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1185-x · Cited by 27
Metadata
- Authors
- Stowasser, M., Sharman, J., Leano, R., Gordon, R. D., Ward, G., Cowley, D., & Marwick, T. H.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-09
- Volume
- 90
- Issue
- 9
- Pages
- 5070-5076
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2156608900
- Cited by
- 271
- References
- 52
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.